Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.
Human papillomavirus (HPV)-specific antibodies are proposed to be the correlate of protection afforded by HPV L1 virus-like particle (VLP) vaccines. Previous studies have characterized the systemic antibody response to immunization in terms of both the quantity and the ability to neutralize HPV. Here, we have adapted a generalized memory B cell ELISPOT to the HPV16 system and expanded the analysis of the systemic antibody response to include an avidity measurement of HPV L1 VLP-specific antibodies. We show the results of the memory B cell ELISPOT significantly correlated with IgG and neutralizing antibody titers, but not with the avidity measurement. This is the first comprehensive study to correlate a variety of humoral aspects potentially associated with protective immunity following vaccination with a HPV16 L1 VLP vaccine.
Dauner
Joseph G
JG
HPV Immunology Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD 21702, USA.
Pan
Yuanji
Y
Hildesheim
Allan
A
Harro
Clayton
C
Pinto
Ligia A
LA
D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology*; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D000917:Antibody Formation / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology*; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects* / Q000276:immunology; D030361:Papillomavirus Infections / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D014611:Vaccination
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines